A carregar...
CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient
Trastuzumab is regarded as the primary therapy for patients with HER2-enriched breast cancer, but the pathological complete response for advanced cases is less than 30%. The underlying mechanism of trastuzumab resistance remains unclear and there are currently no conclusive biomarkers for patient re...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5444696/ https://ncbi.nlm.nih.gov/pubmed/27447863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10719 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|